Axicabtagene Ciloleucel
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Axicabtagene Ciloleucel |
| DrugBank ID | DB13915 |
| Brand Names (EU) | Yescarta |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 91.39% |
Approved Indication (EMA)
Yescarta is indicated for the treatment of adult patients with diffuse large B cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. Yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) DLBCL and primary mediastinal large B cell lymphoma (PMBCL), after two or more lines of systemic therapy. Yescarta is indicated for the treatment of adult patients wi
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | Crohn’s colitis | 91.39% | DL |
| 2 | multiple endocrine neoplasia | 91.34% | DL |
| 3 | idiopathic aplastic anemia | 89.69% | DL |
| 4 | adrenal gland hyperfunction | 88.34% | DL |
| 5 | HER2 positive breast carcinoma | 88.02% | DL |
| 6 | ankylosing spondylitis | 87.11% | DL |
| 7 | lymphoadenopathic mastocytosis with eosinophilia | 87.04% | DL |
| 8 | systemic mastocytosis | 87.00% | DL |
| 9 | Smouldering systemic mastocytosis | 86.83% | DL |
| 10 | rheumatoid vasculitis | 86.24% | DL |
| 11 | normal breast-like subtype of breast carcinoma | 85.85% | DL |
| 12 | progesterone-receptor positive breast cancer | 85.85% | DL |
| 13 | breast tumor luminal A or B | 85.64% | DL |
| 14 | hypermobility of coccyx | 85.64% | DL |
| 15 | polyarticular juvenile rheumatoid arthritis | 85.59% | DL |
| 16 | inflammatory spondylopathy | 85.54% | DL |
| 17 | multifocal choroiditis | 85.49% | DL |
| 18 | drug-induced osteoporosis | 85.45% | DL |
| 19 | progesterone-receptor negative breast cancer | 85.12% | DL |
| 20 | psoriasis | 85.06% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.